Is Generate Biomedicines, Inc. (GENB) a Buy, Sell, or Hold?
NASDAQ : GENB
Generate Biomedicines, Inc.
$13.4 USD
-$0.43 (-3.11%)
- Volume
- 321.46K
- Average Volume
- 785.35K
- Market Capitalization
- $1.72B
- P/E Ratio
- -2.69
- Dividend Yield
- 0.00%
- Price Target
- $23.50
- Year High
- $18.18
- Year Low
- $11.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.85
Company Overview
NASDAQ
Michael T. Nally
Biotechnology
Healthcare
GENB
312
US
USD
Liquidity Metrics
-0.11
2.85
2.85
1.48
0.00
Sales & Valuation
$31.89M
53.86
-1.09
-8.42
-4.08
Profitability
-$4.98
-$203.15M
-636.99%
-698.59%
38.68%
-61.53%
P/E Metrics
-2.69
-0.03
-0.03
Analyst Price Target & Rating
$23.50
$25.00
$22.00
1/5
2 Analysts
-42.98%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
$1.66B
52.20
-7.98
2.85
38.68%
-89.38%
-30.27%
-11.88%
0 days
Company Executives
| Name | Title |
|---|---|
| Gevorg Grigoryan | Co-Founder & CTO |
| Jason E. Silvers | President & CFO |
| Molly Gibson | Co-Founder |
| Noubar Afeyan | Co-founder & Independent Chair of the Board |
| Michael T. Nally | CEO & Director |
| Beth Grous | Chief People Officer |
| Sahm Nasseri | Senior Vice President of Business Development & Strategy |
| Aarif Khakoo | Chief Scientific Officer |
| Daria Hazuda | Senior Vice President of Discovery Strategy |
| Sean W. Martin | Secretary, Chief Legal Officer & General Counsel |
Poll Results
No votes yet today — be the first to share your view!
About Generate Biomedicines, Inc. (NASDAQ:GENB) Stock
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdle ... s beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
2026-07-11 11:37:00
The chipmaker has active interests in the healthcare market, including a partnership with Eli Lilly and an investment in small biotech Generate Biomedicines. Nvidia CEO Jensen Huang sees a powerful intersection between health and AI.
2026-06-22 08:00:00
Newly Constructed Phase 2 now 100% Leased Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination BOSTON, June 22, 2026 /PRNewswire/ -- IQHQ, Inc. today announced that AdvanCell has signed a long-term ~128,000 square foot lease for the entire 1 Corporate Drive building at Innovation Park, IQHQ's premier life science and advanced manufacturing campus in Andover, Massachusetts. The transaction is one of the largest life science leases in Greater Boston this year and brings the newly constructed Phase 2 of Innovation Park to 100% leased.
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer
2026-05-31 16:17:57
This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
2026-05-28 16:20:00
SOMERVILLE, Mass., May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) today announced that it intends to participate in the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026.
2026-05-07 06:16:00
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T); developed in collaboration with Roswell Park Comprehensive Cancer Center Approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026 SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March 31, 2026, and highlighted progress across its clinical portfolio.
Frequently Asked Questions
-
What is the current Generate Biomedicines, Inc. (GENB) stock price?
-
Generate Biomedicines, Inc.(NASDAQ:GENB) stock price is $13.4 in the last trading session. During the trading session, GENB stock reached the peak price of $18.18 while $11 was the lowest point it dropped to. The percentage change in GENB stock occurred in the recent session was --3.11% while the dollar amount for the price change in GENB stock was -$0.43.
-
GENB's industry and sector of operation?
-
The NASDAQ listed GENB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GENB?
-
Gevorg Grigoryan | Co-Founder & CTO
Jason E. Silvers | President & CFO
Molly Gibson | Co-Founder
Noubar Afeyan | Co-founder & Independent Chair of the Board
Michael T. Nally | CEO & Director -
How many employees does GENB have?
-
Number of GENB employees currently stands at 312. GENB operates from 101 South Street, Somerville, MA 02143, US.
-
Link for GENB official website?
-
Official Website of GENB is: https://generatebiomedicines.com
-
How do I contact GENB?
-
GENB could be contacted at phone #1 888 469 0055 and can also be accessed through its website. GENB operates from 101 South Street, Somerville, MA 02143, US.
-
How many shares of GENB are traded daily?
-
The average number of GENB shares traded daily for last 3 months was 785.35K.
-
What is the market cap of GENB currently?
-
The market value of GENB currently stands at $1.72B with its latest stock price at $13.4